GeneDx Holdings (WGS) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to -$0.27.
- GeneDx Holdings' EPS (Weighted Average and Diluted) rose 12.90% to -$0.27 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.09, marking a year-over-year increase of 102.89%. This contributed to the annual value of -$1.94 for FY2024, which is 73.17% up from last year.
- Per GeneDx Holdings' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.27 for Q3 2025, which was down 175.00% from $0.36 recorded in Q2 2025.
- In the past 5 years, GeneDx Holdings' EPS (Weighted Average and Diluted) registered a high of $0.98 during Q4 2021, and its lowest value of -$348.82 during Q1 2021.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.78 (2024), whereas its average is -$0.87.
- In the last 5 years, GeneDx Holdings' EPS (Weighted Average and Diluted) slumped by 4,300.00% in 2022 and then surged by 132.73% in 2025.
- GeneDx Holdings' EPS (Weighted Average and Diluted) (Quarterly) stood at $0.98 in 2021, then plummeted by 3,056.12% to -$28.97 in 2022, then spiked by 96.82% to -$0.92 in 2023, then soared by 125.00% to $0.23 in 2024, then grew by 12.90% to -$0.27 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.27 in Q3 2025, compared to $0.36 in Q2 2025 and -$0.23 in Q1 2025.